BridgeBio Pharma, Inc.
(NASDAQ : BBIO)

( )
BBIO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.78%135.800.0%$896.66m
AMGNAmgen, Inc. 0.02%253.051.5%$851.98m
GILDGilead Sciences, Inc. -0.83%64.471.0%$544.83m
VRTXVertex Pharmaceuticals, Inc. -0.44%269.651.9%$487.72m
REGNRegeneron Pharmaceuticals, Inc. -1.08%683.442.6%$434.54m
ILMNIllumina, Inc. 0.48%243.573.3%$313.46m
NVAXNovavax, Inc. 2.04%47.0775.7%$258.44m
BIIBBiogen, Inc. 0.92%204.221.8%$232.70m
BNTXBioNTech SE 2.25%158.150.0%$210.98m
SNSSSunesis Pharmaceuticals, Inc. 6.60%2.100.7%$146.80m
EXASEXACT Sciences Corp. 2.95%49.8617.7%$128.20m
TECHBio-Techne Corp. 3.55%365.324.5%$100.31m
TXG10X Genomics, Inc. 3.23%47.350.0%$95.11m
BMRNBioMarin Pharmaceutical, Inc. -0.09%78.864.2%$94.54m
CRSPCRISPR Therapeutics AG 1.25%55.230.6%$80.40m

Company Profile

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.